从NIK与PPARα互作调控肝脏脂质代谢稳态角度研究去脂软肝方防治非酒精性脂肪肝分子机制

批准号:
81960816
项目类别:
地区科学基金项目
资助金额:
33.0 万元
负责人:
王维
依托单位:
学科分类:
中西医结合临床基础
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
王维
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
脾虚血瘀为高脂饮食下非酒精性脂肪肝(NAFLD)中医关键病机之一。我们的前期研究证明以健脾祛瘀为治法拟定的去脂软肝方可通过激活脂质氧化、降低炎症反应有效治疗NAFLD。由于过氧化物酶体增殖激活受体α(PPARα)激活后调控下游脂质代谢关键基因表达,可减少肝脏脂质沉积;活化的NF-κB诱导激酶(NIK)则通过NF-κB通路加剧脂质过氧化及炎症反应。NIK/PPARa间存在相互制约关系,在肝脏脂质代谢稳态失衡诱发NAFLD中具有重要作用。为此提出去脂软肝方可通过调节NIK/PPARα互作影响下游关键基因表达,维持肝脏脂质代谢稳态防治NAFLD的科学假说。本研究拟复制高脂诱导NAFLD大鼠模型和L0-2细胞模型,探讨去脂软肝方对NIK/PPARα及下游基因表达的影响,在转染报告基因的HepG2细胞中探明其调节NIK/PPARα互作机理,在动物整体和细胞分子水平阐释该方防治NAFLD分子机制。
英文摘要
Spleen deficiency and blood stasis is one of the key pathogenesis of non-alcoholic fatty liver disease (NAFLD) caused by high-fat diet in traditional Chinese medicine. Qu Zhi Ruan Gan (QZRG) Formula which aims to invigorate spleen and remove stasis, shows significantly positive effect on prevention and treatment of NAFLD though activating lipid oxidation, reducing blood lipid and alleviating the inflammation by our previous studies. Since peroxisome proliferator-activated receptor alpha (PPARα) regulates the expression of key lipid metabolism genes in downstream, it can reduce liver lipid deposition. Meanwhile activated NF-κB-inducing kinase (NIK) enhances lipid peroxidation and inflammation through the NF-κB pathway. NIK/PPARα interacted and influenced with each other, which plays a significant role in NAFLD induced by lipid homeostasis imbalance in liver. Based on all above backgrounds, we propose the hypothesis that the QZRG Formula can ameliorate and sustain homeostasis of liver lipid metabolism in NAFLD rats effectively though regulating NIK/PPARα interaction. By moderating the NIK/PPARα interaction, it can affect downstream genes expression including lipid metabolism and inflammation. In order to verify the hypothesis, this study will be replicating the high-fat diet induced NAFLD rat model and culturing high FFA L0-2 cell line to validate the effects of QZRG Formula on NIK/PPARα and downstream gene expression. Meanwhile, QZRQ Formula mediating the mechanism of NIK/PPARαinteraction will be validated in HepG2 cell line transfected with reporter gene in vitro. This study aims at illustrating the molecular mechanism of prevention and treatment of NAFLD by QZRG Formula and will provide the theory basis of multi-link and multi-level treatments of NAFLD by Chinese medicine Formula.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:--
发表时间:2021
期刊:中华中医药杂志
影响因子:--
作者:段旭冰;陈文慧;王仕奇;张雯婷;刘潇;王维
通讯作者:王维
DOI:10.13422/j.cnki.syfjx.20202121
发表时间:2020
期刊:中国实验方剂学杂志
影响因子:--
作者:冯晓异;魏宁颐;赵微;王维
通讯作者:王维
DOI:10.19288/j.cnki.issn.1000-2723.2021.02.005.
发表时间:2021
期刊:云南中医学院学报
影响因子:--
作者:杨艳;洪力;韦姗姗;姚政;季能博;徐寻;吕一航;王维
通讯作者:王维
DOI:--
发表时间:2023
期刊:亚太传统医药
影响因子:--
作者:罗容;吕一航;李丰源;田源;杨艳;宋一男;王蓓蓓;王维
通讯作者:王维
DOI:--
发表时间:2021
期刊:中西医结合肝病杂志
影响因子:--
作者:洪力;姚政;杜冰;刘国华;韦姗姗;杨艳;张晨阳;王维
通讯作者:王维
去脂软肝方基于“脾主肌肉”理论从AMPK信号通路防治代谢相关脂肪性肝病合并骨骼肌减少症分子机制研究
- 批准号:82360886
- 项目类别:地区科学基金项目
- 资助金额:32万元
- 批准年份:2023
- 负责人:王维
- 依托单位:
国内基金
海外基金
